Thema: Presse: Preclinical Data From GVAX Cancer Vaccine
Presse: Preclinical Data From GVAX Cancer Vaccine
Tom[a]
27.03.2004 19:56:47
Preclinical Data From GVAX Cancer Vaccine And Other Programs
At 2004 American Association For Cancer Research
Cell Genesys, Inc. today announced that each of its five submitted abstracts have been accepted for presentation at the 2004 American Association for Cancer Research (AACR) Annual Meeting which will take place in Orlando, FL, March 27 through March 31. The five abstracts to be presented by Cell Genesys scientists are as follows:
-- Enhancement of GM-CSF secreting tumor cell vaccines by docetaxel
through immune-dependent and independent mechanisms. (To be presented in a poster discussion by Rodney Prell, Ph.D. -- Monday, March 29, 8:00am - 12:00pm EST) (Abstract ID: 2195)
-- Oncolytic adenovirus CG5757 for the treatment of retinoblastoma (Rb)
pathway-defective and telomerase-positive cancers. (To be presented in
mini-symposia by Yuanhao Li, Ph.D. -- Monday, March 29, 9:40am EST)
(Abstract ID: 2337)
-- Adeno-associated virus (AAV) vector mediated gene transfer of soluble
VEGF receptors for the treatment of glioblastoma multiforme. (To be
presented in a poster discussion by Thomas Harding, Ph.D. -- Monday,
March 29, 1:00pm - 5:00pm EST) (Abstract ID: 2560)
-- Adeno-associated viral (AAV)-mediated gene delivery of soluble vascular
endothelial growth factor receptor 3 (sVEGFR3) inhibits development of
lymph node metastases. (To be presented in mini-symposia by JianMin
Lin, Ph.D. -- Monday, March 29, 2:40 pm EST) (Abstract ID: 2377)
-- Development of an orthotopic bladder tumor model in mice and
demonstration of antitumor efficacy with an oncolytic adenovirus CG8840
for the treatment of bladder cancer. (To be presented in a poster
discussion by Nagarajan Ramesh, Ph.D. -- Wednesday, March 31,
8:00am - 12:00pm EST) (Abstract ID: 5134)
"We are pleased to have the opportunity to present progress reports from our preclinical programs in cancer biological therapies," stated Peter K. Working, Ph.D., senior vice president, research and development at Cell Genesys. "While our business focus remains on our clinical-stage programs in GVAX(R) cancer vaccines and oncolytic virus therapies, our deep product pipeline represents opportunities for the future growth of our business."
Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX(R) cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX(R) vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX(R) cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys´ majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN.
At 2004 American Association For Cancer Research
Cell Genesys, Inc. today announced that each of its five submitted abstracts have been accepted for presentation at the 2004 American Association for Cancer Research (AACR) Annual Meeting which will take place in Orlando, FL, March 27 through March 31. The five abstracts to be presented by Cell Genesys scientists are as follows:
-- Enhancement of GM-CSF secreting tumor cell vaccines by docetaxel
through immune-dependent and independent mechanisms. (To be presented in a poster discussion by Rodney Prell, Ph.D. -- Monday, March 29, 8:00am - 12:00pm EST) (Abstract ID: 2195)
-- Oncolytic adenovirus CG5757 for the treatment of retinoblastoma (Rb)
pathway-defective and telomerase-positive cancers. (To be presented in
mini-symposia by Yuanhao Li, Ph.D. -- Monday, March 29, 9:40am EST)
(Abstract ID: 2337)
-- Adeno-associated virus (AAV) vector mediated gene transfer of soluble
VEGF receptors for the treatment of glioblastoma multiforme. (To be
presented in a poster discussion by Thomas Harding, Ph.D. -- Monday,
March 29, 1:00pm - 5:00pm EST) (Abstract ID: 2560)
-- Adeno-associated viral (AAV)-mediated gene delivery of soluble vascular
endothelial growth factor receptor 3 (sVEGFR3) inhibits development of
lymph node metastases. (To be presented in mini-symposia by JianMin
Lin, Ph.D. -- Monday, March 29, 2:40 pm EST) (Abstract ID: 2377)
-- Development of an orthotopic bladder tumor model in mice and
demonstration of antitumor efficacy with an oncolytic adenovirus CG8840
for the treatment of bladder cancer. (To be presented in a poster
discussion by Nagarajan Ramesh, Ph.D. -- Wednesday, March 31,
8:00am - 12:00pm EST) (Abstract ID: 5134)
"We are pleased to have the opportunity to present progress reports from our preclinical programs in cancer biological therapies," stated Peter K. Working, Ph.D., senior vice president, research and development at Cell Genesys. "While our business focus remains on our clinical-stage programs in GVAX(R) cancer vaccines and oncolytic virus therapies, our deep product pipeline represents opportunities for the future growth of our business."
Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX(R) cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies. Clinical trials of GVAX(R) vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX(R) cancer vaccines, oncolytic virus therapies and antiangiogenesis therapies for multiple types of cancer. Cell Genesys´ majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN.
Tom[a]
